Patents by Inventor Marine LE CLECH

Marine LE CLECH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTIGEN BINDING MOLECULES COMPRISING ANTI-FAP CLONE 212
    Publication number: 20220227878
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: December 21, 2021
    Publication date: July 21, 2022
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Harald DUERR, Christian KLEIN, Pablo UMANA, Alexander BUJOTZEK, Joerg ZIELONKA, Christine TRUMPFHELLER, Moritz RAPP, Marine LE CLECH
  • Bispecific antigen binding molecules comprising anti-FAP clone 212
    Patent number: 11242396
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 30, 2019
    Date of Patent: February 8, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Peter Bruenker, Harald Duerr, Christian Klein, Pablo Umana, Alexander Bujotzek, Joerg Zielonka, Christine Trumpfheller, Moritz Rapp, Marine Le Clech
  • Bispecific antigen binding molecules comprising anti-FAP clone 212
    Publication number: 20200190207
    Abstract: The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.
    Type: Application
    Filed: September 30, 2019
    Publication date: June 18, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Peter BRUENKER, Harald DUERR, Christian KLEIN, Pablo UMANA, Alexander BUJOTZEK, Joerg ZIELONKA, Christine TRUMPFHELLER, Moritz RAPP, Marine LE CLECH
  • COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20200095313
    Abstract: The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.
    Type: Application
    Filed: December 11, 2019
    Publication date: March 26, 2020
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Emily Rana CORSE, Olivier FREYTAG, Christian GERDES, Marine LE CLECH, Hyam LEVITSKY, Marion OTT, Martin STERN, Wei XU
  • COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20180051077
    Abstract: The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.
    Type: Application
    Filed: October 2, 2017
    Publication date: February 22, 2018
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Emily Rana Corse, Olivier Freytag, Christian Gerdes, Marine Le Clech, Hyam Levitsky, Marion OTT, Martin Stern, Wei Xu
  • COMBINATION THERAPY OF ANTIBODIES ACTIVATING HUMAN CD40 AND ANTIBODIES AGAINST HUMAN PD-L1
    Publication number: 20160045597
    Abstract: The present invention relates to a pharmaceutical product for the treatment of a proliferative disease, comprising the combination of an antibody, or an antigen-binding portion thereof, that specifically binds to human CD40; and a PD-L1 antibody; and optionally a 3rd component which comprises as an active ingredient a cytokine inhibitor.
    Type: Application
    Filed: August 14, 2015
    Publication date: February 18, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Emily Rana CORSE, Olivier FREYTAG, Christian GERDES, Marine LE CLECH, Hyam LEVITSKY, Marion OTT, Martin STERN, Wei XU